Inovio Pharmaceuticals Inc  

(Public, NASDAQ:INO)   Watch this stock  
Find more results for infection
4.56
-0.16 (-3.39%)
After Hours: 4.56 0.00 (0.00%)
Nov 20, 4:57PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.50 - 4.76
52 week 4.20 - 9.86
Open 4.74
Vol / Avg. 1.06M/1.16M
Mkt cap 411.75M
P/E     -
Div/yield     -
EPS -1.18
Shares 90.30M
Beta 2.91
Inst. own 32%
Dec 6, 2017
Inovio Pharmaceuticals Inc at Citi Global Healthcare Conference Add to calendar
Nov 29, 2017
Inovio Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - 9:00AM EST - Add to calendar
Nov 15, 2017
Inovio Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 8, 2017
Q3 2017 Inovio Pharmaceuticals Inc Earnings Call
Sep 26, 2017
Inovio Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 11, 2017
Inovio Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Sep 6, 2017
Inovio Pharmaceuticals Inc, Aduro Biotech Inc, Five Prime Therapeutics Inc & Mirati Therapeutics Inc at Citi Biotech Conference - Panel - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -1290.76% -208.49%
Operating margin -1103.61% -215.55%
EBITD margin - -209.59%
Return on average assets -75.53% -38.05%
Return on average equity -95.93% -49.33%
Employees 239 -
CDP Score - -

Address

10480 Wateridge Cir
SAN DIEGO, CA 92121-5773
United States - Map
+1-858-5976006 (Phone)
+1-858-4041392 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Officers and directors

Jong Joseph Kim Ph.D. President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Peter D. Kies Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Niranjan Y. Sardesai Ph.D. Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Mark L. Bagarazzi M.D. Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Avtar S. Dhillon M.D. Non-Executive Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
George W. Bickerstaff III Director
Age: 61
Bio & Compensation  - Reuters
David B. Weiner Director
Age: 61
Bio & Compensation  - Reuters
Simon X. Benito Independent Director
Age: 72
Bio & Compensation  - Reuters
Angel Cabrera Ph.D. Independent Director
Age: 49
Bio & Compensation  - Reuters